{
    "title": "115_s1048",
    "content": "The \"Enhanced Clinical Trial Design Act of 2017\" may be cited as the Act. Patient access to experimental treatments is addressed in the Act. The \"Enhanced Clinical Trial Design Act of 2017\" mandates a public meeting within 180 days to discuss clinical trial inclusion and exclusion criteria, with a report on topics to be provided within 30 days. The \"Enhanced Clinical Trial Design Act of 2017\" requires a public meeting to discuss exclusion criteria, benefits and risks of alternative trial designs, barriers to participation, and methods to increase enrollment of diverse patient populations in clinical trials. The \"Enhanced Clinical Trial Design Act of 2017\" mandates a public meeting to address the impact of changes in clinical trial inclusion and exclusion criteria on trial complexity and duration. The Comptroller General of the United States is required to report on individual access to investigational drugs through the expanded access program within a year of the Secretary's report on the public meeting topics. The curr_chunk discusses actions taken by manufacturers under section 561A of the Federal Food, Drug, and Cosmetic Act, the impact of Form FDA 3926 and guidance on access to investigational drugs, improvements in access for individual patients, and an assessment of patients and healthcare providers. The Secretary will issue draft guidances on eligibility criteria for clinical trials within 180 days of the report's publication. The guidance will address broadening eligibility criteria, especially for drugs treating serious conditions. The draft guidance will address broadening eligibility criteria for clinical trials, focusing on treating serious conditions and increasing trial recruitment to accurately reflect eligible patients. The Secretary of Health and Human Services will issue guidance to streamline institutional review board review for individual patient expanded access protocols. This includes conditions for review and the use of centralized boards. Additionally, there will be updates to relevant forms. SEC. 4. EXPANDED ACCESS POLICY TRANSPARENCY. Amends the Federal Food, Drug, and Cosmetic Act to expedite the review process for drugs designated as breakthrough therapy, fast track product, or regenerative advanced therapy."
}